Cybin to Host November Investor Call for Q2 Financial Results and Business Update

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) announced it will host a conference call and webcast on November 13, 2025, at 8 a.m. ET to review financial results for its second quarter ended September 30, 2025, and provide a comprehensive business update. This quarterly reporting event comes at a critical juncture for the neuropsychiatry company as it advances multiple late-stage clinical programs targeting significant mental health conditions.

The timing of this investor call is particularly important given Cybin's position as a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare. The company is developing new and innovative next-generation treatment options to address the large unmet need for people suffering from mental health conditions. With mental health disorders affecting millions globally and traditional treatments often providing inadequate relief, Cybin's approach represents a potential paradigm shift in psychiatric care.

Central to Cybin's development pipeline is CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over existing therapies for serious conditions. The company also has CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder, another condition affecting millions worldwide with limited effective treatment options.

Investors and industry observers will be watching closely for updates on these clinical programs during the November call, as positive data could significantly impact both patient care and the company's valuation. The mental health treatment market represents a multi-billion dollar opportunity, and successful development of novel therapies could position Cybin as a leader in the emerging neuropsychiatry space. Additional information about Cybin's developments is available in the company's newsroom.

The broader implications of Cybin's work extend beyond financial markets to public health. Mental health disorders represent one of the largest burdens on global healthcare systems, with depression alone being a leading cause of disability worldwide. Current treatments often come with significant side effects and limited efficacy, creating an urgent need for innovative approaches. Cybin's focus on developing novel compounds that provide effective and durable results for patients addresses this critical healthcare gap.

Founded in 2019, Cybin has established operational presence across Canada, the United States, the United Kingdom and Ireland, reflecting the global nature of both the mental health challenge and the potential market for effective treatments. The company's research pipeline includes additional investigational compounds focused on 5-HT receptors, suggesting a comprehensive approach to neuropsychiatric drug development. The full press release detailing the upcoming investor call can be viewed at https://ibn.fm/BqH38.